Veradermics, Incorporated
Veradermics, Incorporated
- Market cap
- $5.27B
Your view on MANE
Overview
What the company does, where it operates, and who runs it.
About Veradermics, Incorporated
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Reid Waldman
- Headquarters
- 470 James Street, New Haven, CT, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Reid Waldman
- Headquarters
- 470 James Street, New Haven, CT, US
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics.
A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts.
Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis.
Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Veradermics, Incorporated. Starting points for Veradermics, Incorporated: EPS -$2.22, beta 1.23 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Veradermics, Incorporated. Trailing twelve-month EPS for Veradermics, Incorporated stands at -$2.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$174.00
average of 3 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy6
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | −$0.61 | −$0.60 | −$2.72 | −$2.66 |
| Low estimate | −$0.61 | −$0.60 | −$11.48 | −$11.22 |
| High estimate | −$0.61 | −$0.60 | −$0.22 | −$0.21 |
| No. of analysts | 3 | 1 | 3 | 4 |
| Year-ago EPS | −$1.63 | −$1.321 | −$111.911 | — |
| Growth | +62.3% | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $0.00 | $12.47M |
| Low estimate | $0.00 | $0.00 | $0.00 | $3.64M |
| High estimate | $0.00 | $0.00 | $0.00 | $43.32M |
| No. of analysts | 0 | 0 | 0 | 6 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Veradermics, Incorporated. Veradermics, Incorporated has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ABEOAbeona Therapeutics Inc. | Healthcare | Biotechnology | $156.0M | ||
| ADILAdial Pharmaceuticals, Inc. | Healthcare | Biotechnology | $13.3M | ||
| DRMADermata Therapeutics, Inc. | Healthcare | Biotechnology | $2.7M | ||
| HELPCybin Inc. Common Stock | Healthcare | Medical - Pharmaceuticals | $427.1M | ||
| LSTALisata Therapeutics, Inc. | Healthcare | Biotechnology | $8.8M | ||
| OVIDOvid Therapeutics Inc. | Healthcare | Biotechnology | $426.5M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $80.3M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ZLDAFZelira Therapeutics Limited | Healthcare | OTC | $5.0M | ||
| ZLDPFZealand Pharma A/S | Healthcare | OTC | $4.0B | ||
| ZNTLZentalis Pharmaceuticals, Inc. | Healthcare | NASDAQ | $133.6M | ||
| ZURAZura Bio Limited | Healthcare | NASDAQ | $93.0M | ||
| ZVRAZevra Therapeutics, Inc. | Healthcare | NASDAQ | $552.2M | ||
| ZVSAZyVersa Therapeutics, Inc. | Healthcare | OTC | $1.1M | ||
| ZYMEZymeworks Inc. | Healthcare | NASDAQ | $1.8B | ||
| VSBCVitaSpring Biomedical Co. Ltd. | Healthcare | OTC | $2.3M | ||
| VSTMVerastem, Inc. | Healthcare | NASDAQ | $865.7M | ||
| VTGNVistaGen Therapeutics, Inc. | Healthcare | NASDAQ | $9.2M | ||
| VTIAFFamiCord AG | Healthcare | OTC | $111.1M | ||
| VTVTvTv Therapeutics Inc. | Healthcare | NASDAQ | $64.2M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.10% | |
| XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged) | $627M in assets | 0.10% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.05% | |
| LFSCF/M Emerald Life Sciences Innovation ETF | $125M in assets | 3.87% | |
| SBIOALPS Medical Breakthroughs ETF | $187M in assets | 3.61% | |
| TOSThe RBB Fund Trust - Twin Oak Strategic Solutions ETF | $146M in assets | 2.81% | |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $516M in assets | 2.66% | |
Largest holders first, then the funds most concentrated in MANE.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Veradermics, Incorporated, and how their positions are changing. At a $5.27B market value, institutional positions materially move Veradermics, Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Veradermics, Incorporated executives and directors. Shares of Veradermics, Incorporated have traded between $32.00 and $131.24 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Veradermics, Incorporated. Coverage tracks Veradermics, Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Veradermics, Incorporated.